Enliven Therapeutics (ELVN) Equity Ratio (2019 - 2026)

Enliven Therapeutics has disclosed Equity Ratio across 8 years of filings, most recently posting 0.98 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.98, up 2.36% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.98 (up 2.36% YoY), and the FY2025 annual result was 0.97, up 1.48% from the prior year.
• Equity Ratio came in at 0.98 for Q1 2026 at Enliven Therapeutics, up from 0.97 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2026 to a low of 1.15 in Q3 2022.
• The 5-year median for Equity Ratio is 0.95 (2024), against an average of 0.52.
• Across the five-year window, Equity Ratio slumped 224.09% in 2022 and jumped 255.14% in 2023, its largest moves.
• Enliven Therapeutics' Equity Ratio stood at 0.92 in 2022, then soared by 198.07% to 0.9 in 2023, then gained by 5.16% to 0.95 in 2024, then rose by 1.48% to 0.97 in 2025, then advanced by 1.04% to 0.98 in 2026.
• The last three Equity Ratio figures came in at 0.98 (Q1 2026), 0.97 (Q4 2025), and 0.97 (Q3 2025), per Business Quant data.